Chapter 38: Drugs Acting on Renin-Angiotensin-Aldosterone System Flashcards
ACEI
captopril (Capoten),
enalapril (Vasotec),
fosinopril (Monopril),
lisinopril (Prinivil,Zesteril),
ramipril (Altace)
Cardiac medications
-pril drugs
Block RAAS system
Top line tx for HTN
ACEI MOA
Inhibits angio converting enzyme, interfering w/ conversion of angiotensin 1 to angiotensin II
ACEI use
HTN, Heart Failure. Reduce mortality in MI, Diabetic and nondiabetic nepropathy, reduces the risk for MI and stroke
ACEI SE
dizziness
hypotension
irritating cough (~30% of people get irritating, dry cough secondary to bradykinin secretion. Most common reason for d/c.)
hyperkalemia (Lose Na and water. Hold onto K),
renal failure (Renal failure in renal artery stenosis –need high levels of renin and constriction in efferent arterioles. If not, can progress into worse renal failure.)
peripheral vasodilation (edema)
angioedema (Angioedema in 1-5% of pt. fatal reaction. Increase permeability and edema that mainly effects mouth and throat. Swollen lips and gums. D/c and NEVER use again –does not just happen with first dose.)
neutropenia -rare
ACEI safety and monitoring
BUN/Cr, K+, BP –any increase consider d/c
contraindications for ACEI
K sparing diuretic, Salt substitutes
Angiotensin II receptor blockers (ARBs)
Losartan potassium (Cozaar)
Valsartan (Diovan)
-sartan drugs
Block RAAS
Less potent than ACEI
ARBs uses
HTN, CHF, diabetic nephropathy, MI and prevention of MI and stroke
Vasodilation = decrease in BP. Coronary arteries open up –helpful for angina or MI.
ARBs SE
Angioedema, Renal Failure, Dizziness, hypotension, hyperkalemia.
May also cause cough -Only ~ 10% of patient get a cough. If patient gets a cough with ACEI, will try them on ARB . Another reason to swtich to ARB from ACEI is if ACEI is too potent and pt has hypotension.
ARBs MOA
Function similar to ACE inhibitors. Selectively antagonizes angiotensin II receptors.
lower BP and increase blood to heart. block vasoconstriction.
DRI MOA
aliskiren
inhibit renin from converting angiotensinogen to angiotensin I
ARB safety and monitoring
BUN/Cr, K, BP
caution in RF patient
aldosterone antagonist MOA
spironolactone, eplernone
block aldosterone from target cells
ACEI and ARB prescribing considerations
*Therapeutic Goal: Decrease BP in patient with HTN, improve hemodynamics in patients with HF and reduce mortality
*Baseline Data: Determine BP and renal function
*Monitoring: Consider checking Creatinine 2-4 weeks after starting. Have patients track BP values.
*Identify High Risk Patients: Contraindicated in pregnancy and in patient with bilateral renal artery stenosis. Hold in K> 5, Cr > 2.
*Evaluating Therapeutic Effects: Monitor for decreased BP
*Minimizing adverse effects: Instruct patient to consult the prescriber if experiencing cough or facial swelling. Use cautiously in combination with other meds that cause increased K+